Frank Hodi

Trials

Studies that name Frank Hodi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:06 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT01026324 · Dinaciclib in Treating Patients With Stage III-IV Melanoma

  National Cancer Institute (NCI) · terminated · Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma · principal investigator
• Ph1
  NCT00039091 · Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

  National Cancer Institute (NCI) · terminated · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Cancer Immune Monitoring and Analysis Center
  U24CA224331 · NCI · DANA-FARBER CANCER INST · fiscal years 2017 to 2026 · $1,934,873 awarded in 2026
  Same name and institution; not confirmed by an ID
• Program 35: Melanoma
  P30CA006516 · NCI · DANA-FARBER CANCER INST · fiscal years 2017 to 2026 · $48,198 awarded in 2026
  Grant number is on one of their registry trials
• Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma
  R21CA143832 · NCI · DANA-FARBER CANCER INST · fiscal years 2010 to 2011 · $323,248 awarded in 2011
  Same name and institution; not confirmed by an ID
• CTLA-4 Blockade in GM-CSF Vaccinated Patients
  R21CA105776 · NCI · DANA-FARBER CANCER INST · fiscal years 2003 to 2004 · $364,678 awarded in 2004
  Grant number is on one of their registry trials
• MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATION
  K08CA078880 · NCI · DANA-FARBER CANCER INST · fiscal years 1998 to 2002 · $87,426 awarded in 2002
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
  U01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 1994 to 2013
  Named on NCT01026324